James Matcham

5.1k total citations · 1 hit paper
26 papers, 1.3k citations indexed

About

James Matcham is a scholar working on Hematology, Statistics and Probability and Economics and Econometrics. According to data from OpenAlex, James Matcham has authored 26 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 11 papers in Statistics and Probability and 7 papers in Economics and Econometrics. Recurrent topics in James Matcham's work include Statistical Methods in Clinical Trials (10 papers), Acute Myeloid Leukemia Research (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). James Matcham is often cited by papers focused on Statistical Methods in Clinical Trials (10 papers), Acute Myeloid Leukemia Research (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). James Matcham collaborates with scholars based in United Kingdom, Germany and France. James Matcham's co-authors include Gerhard Heil, Miguel Á. Sanz, Klaus Lechner, Jeff Szer, Alan Barge, Dieter Hoelzer, John A. Liu Yin, L. Noens, Arnold Ganser and Caroline O’Brien and has published in prestigious journals such as Blood, Nature Reviews Drug Discovery and British Journal of Cancer.

In The Last Decade

James Matcham

25 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of a five-dimensional framework on R&D productivity at AstraZeneca

2018 271 citations Paul Morgan, Dean G. Brown et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Matcham United Kingdom	14	658	320	218	139	121	26	1.3k
Yow‐Ming Wang United States	18	179 0.3×	226 0.7×	350 1.6×	115 0.8×	54 0.4×	54	1.0k
Ekaterina Gibiansky United States	19	177 0.3×	267 0.8×	361 1.7×	123 0.9×	100 0.8×	42	1.3k
Nathalie Gérard France	21	204 0.3×	219 0.7×	304 1.4×	196 1.4×	14 0.1×	58	1.3k
Christophe Schmitt Switzerland	28	2.5k 3.7×	377 1.2×	597 2.7×	842 6.1×	33 0.3×	73	3.8k
Nicolas Frey Switzerland	19	89 0.1×	89 0.3×	237 1.1×	87 0.6×	109 0.9×	48	932
Anja Henningsson Sweden	8	106 0.2×	567 1.8×	197 0.9×	56 0.4×	79 0.7×	12	889
Ruth March United Kingdom	14	54 0.1×	274 0.9×	567 2.6×	49 0.4×	82 0.7×	29	2.1k
Kazuto Ito Japan	32	95 0.1×	466 1.5×	730 3.3×	36 0.3×	58 0.5×	160	3.0k
Dinesh P. de Alwis United States	21	64 0.1×	900 2.8×	517 2.4×	66 0.5×	165 1.4×	37	1.6k

Countries citing papers authored by James Matcham

Since Specialization

Citations

This map shows the geographic impact of James Matcham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Matcham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Matcham more than expected).

Fields of papers citing papers by James Matcham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Matcham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Matcham. The network helps show where James Matcham may publish in the future.

Co-authorship network of co-authors of James Matcham

This figure shows the co-authorship network connecting the top 25 collaborators of James Matcham. A scholar is included among the top collaborators of James Matcham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Matcham. James Matcham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mitchell, Pat, Bengt Hamrén, Gabriel Helmlinger, et al.. (2018). Integrating dose estimation into a decision‐making framework for model‐based drug development. Pharmaceutical Statistics. 17(2). 155–168. 1 indexed citations

Morgan, Paul, Dean G. Brown, Simon Lennard, et al.. (2018). Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery. 17(3). 167–181. 271 indexed citations breakdown →

Love, Sharon, Sarah Brown, Christopher J. Weir, et al.. (2017). Embracing model-based designs for dose-finding trials. British Journal of Cancer. 117(3). 332–339. 44 indexed citations

Sabin, Tony, James Matcham, Andrew Copas, & Mahesh Parmar. (2015). Assessing End of Phase 2 Decision Criteria. Statistics in Biopharmaceutical Research. 7(3). 230–237. 2 indexed citations

Sabin, Tony, James Matcham, Sarah Bray, Andrew Copas, & Mahesh Parmar. (2013). A Quantitative Process for Enhancing End of Phase 2 Decisions. Statistics in Biopharmaceutical Research. 6(1). 67–77. 18 indexed citations

Jenkins, Martin, Aiden Flynn, Trevor Smart, et al.. (2011). A statistician's perspective on biomarkers in drug development. Pharmaceutical Statistics. 10(6). 494–507. 31 indexed citations

O’Kelly, Michael, Steven A. Julious, Stephen Pyke, et al.. (2010). Making available information from studies sponsored by the pharmaceutical industry: some current practices. Pharmaceutical Statistics. 10(1). 60–69. 6 indexed citations

Pyke, Stephen, Steven A. Julious, Simon Day, et al.. (2010). The potential for bias in reporting of industry‐sponsored clinical trials. Pharmaceutical Statistics. 10(1). 74–79. 13 indexed citations

Matcham, James, Steven A. Julious, Stephen Pyke, et al.. (2010). Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry‐sponsored clinical trials. Pharmaceutical Statistics. 10(1). 70–73. 13 indexed citations

10.

Burzykowski, Tomasz, James R. Carpenter, Corneel Coens, et al.. (2009). Missing data: Discussion points from the PSI missing data expert group. Pharmaceutical Statistics. 9(4). 288–297. 21 indexed citations

11.

Matcham, James, Michael McDermott, & Anthony E. Lang. (2007). GDNF in Parkinson's disease: The perils of post-hoc power. Journal of Neuroscience Methods. 163(2). 193–196. 13 indexed citations

12.

Heil, Gerhard, D. Hoelzer, Miguel Á. Sanz, et al.. (2006). Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia. 20(3). 404–409. 15 indexed citations

13.

Favre, Gilles, Meral Beksaç, Andrea Bacigalupo, et al.. (2003). Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplantation. 32(9). 873–880. 67 indexed citations

14.

Hedenus, Michael, Magnus Adriansson, Jesús F. San Miguel, et al.. (2003). Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double‐blind, placebo‐controlled study. British Journal of Haematology. 122(3). 394–403. 267 indexed citations

15.

Kottaridis, PD, Karl S. Peggs, Norbert Schmitz, et al.. (2002). Survival and Freedom from Progression in Autotransplant Lymphoma Patients is Independent of Stem Cell Source: Further Follow-up from the Original Randomised Study to Assess Engraftment. Leukemia & lymphoma. 43(3). 531–536. 2 indexed citations

16.

Archimbaud, E, Oliver G. Ottmann, John A. Liu Yin, et al.. (1999). A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia. Blood. 94(11). 3694–3701. 83 indexed citations

17.

Serke, Stefan, Lubomir Arseniev, Mike Watts, et al.. (1997). Imprecision of counting CFU-GM colonies and CD34-expressing cells. Bone Marrow Transplantation. 20(1). 57–61. 32 indexed citations

18.

Heil, Gerhard, Dieter Hoelzer, Miguel Á. Sanz, et al.. (1997). A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Filgrastim in Remission Induction and Consolidation Therapy for Adults With De Novo Acute Myeloid Leukemia. Blood. 90(12). 4710–4718. 11 indexed citations

19.

Heil, Gerhard, Miguel Á. Sanz, Klaus Lechner, et al.. (1995). Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia. Ghent University Academic Bibliography (Ghent University). 12 indexed citations

20.

Patel, K R, Sourav Ghosh, & James Matcham. (1991). Lack of dose‐response effect of terfenadine on resting bronchomotor tone in patients with asthma. Clinical & Experimental Allergy. 21(3). 363–366. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact